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CYTOMEGALOVIRUS (CMV) disease results from a 
complex interplay among a variety of factors. the 
consequences of which are differences in the incidence and 
severity of CMV disease across different transplant popu-
lations. '-3 In May 1990. the small bowel transplantation 
(Sax) program was initiated at our institution. In this study 
we analyze the incidence and timing of CMV disease after 
sax and we assess risk factors for CMV disease in this 
new transplant population. 
MATERIALS AND METHODS 
Patient Population 
From May 1990 to March 1993.40 patients underwent SBx at the 
University of Pittsburgh Medical Center. Four patients died 
during the first month after transplantation and were excluded 
from the study. The study population included 36 patients who 
received 38 grafts. There were 20 adults and 16 children with an 
age range between 6 months and 50 years. Thirteen patients (36%) 
received an isolated SBx. 18 (50%) received SBx and liver and 5 
(14%) receIved multi visceral grafts. 
Immunosuppression and CMV Prophylaxis 
Immunosuppression included FK 506 and steroids as previously 
described.' Twenty·five patients (69%) were treated also with 
azathioprine. Twenty·two patients received ganciclovir prophy· 
laxis between 21 and 90 days after SBx. Sixteen children and I 
adult received only CMV·seronegative blood products. 
RESULTS 
Fourteen patients t39%) developed 25 episodes of CMV 
disease. Six had a single episode. 5 had 2 episodes. 2 had 
:; episodes. and I had 4 episodes. The first. second. and 
third episodes of CMV disease occurred at a mean of 48 :!: 
23. 131 :!: 68. and 173 :!: 19 days. respectively. after 
transplantation. The types ofCMV disease were: 20 (80%) 
enteritis. 2 (8%) hepatitis. 2 (8%) pneumonitis. and I (4%) 
syndrome. Table I shows the relationship between donor/ 
recipient CMV serologic status and the frequency ofCMV 
disease. 
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Univariate and multivariate analyses to study risk fac-
tors for CMV disease were performed using Cox's propor-
tional hazards model. Factors analyzed included age, type 
of transplantation. donor and recipient serologic status, 
use of ganciclovir prophylaxis. blood products transfused, 
the cumulative blood level of FK 506, and cumulative 
doses (adjusted to weight) of OKT3, azathioprine, and 
pulse and maintenance doses of steroids. Multivariate 
analysis showed that the factors associated with a first 
episode of CMV disease were: CMV-seronegative recipi-
ent of a CMV-seropositive graft (relative risk [RR] 6.4. 
95% confidence interval [CI] 1.7 to 24.7. P = .007). the 
cumulative blood level of FK 506 (RR 2.3,95% CI 1 to 5.2, 
P = .04). the cumulative dose of pulse of steroids (RR 2.6. 
95% CI 1 to 6.9. P = .06) and the cumulative dose of 
maintenance steroids (RR 5.2. 95% CI 1.1 to 23.\. P = 
.03). The only 2 factors independently associated with 
recurrent CMV disease were CMV-seronegative recipient 
of CMV-seropositive graft (RR 10.1. 95% CI 1.9 to 52.5. 
P = .006) and the cumulative doses of steroid boluses 
(RR 15.1.95% CI 1.6 to 125.4. P = .01). 
DISCUSSION 
This study showed that sax transplantation is associated 
with a high incidence of CMV disease. Although the 
morbidity associated with CMV infection is quite variable. 
2 factors have been associated with an elevated incidence 
of CMV disease: primary CMV infection after transplan-
tation and the type and amount of immunosuppression 
given. Primary CMV infection occurred in 73% of CMV-
seronegative recipients who received grafts from CMV· 
seropositive donors. and accounted for 64% of episodes of 
disease. This contrasts with the lack of infection and 
disease in seronegative recipients of seronegative grafts. 
However. the morbidity of CMV infection was also high in 
secondary infections. because 55% of CMs·~eropositive 
recipients developed disease. The multivariate analysis 
showed that the cumulative FK 506 levels. and amount of 
steroid given in boluses and for maintenance. were also 
risk factors for CMV disease. This suggests that the 
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RECURRENT CMV DISEASE 
increased immunosuppression that many of these patients 
required also played an important role in the high inci-
dence of CMY disease after SBx. Because long courses of 
ganciclovir prophylaxis were not sufficient to prevent 
CMY disease. new strategies are needed. A voiding trans-
plantation of CMY -seropositive grafts into CMY -seroneg-
ative recipients and new approaches to prevent overimmu-
nosuppression are 2 potential alternatives to decrease the 
incidence of CMY disease in SBx. 
-------- ---------------------------------
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